Abstract
This report is concerned with the capacities of aciclovir to protect mice challenged intracerebrally with multiple lethal doses of type 1 herpes simplex virus and to control multiplication of this virus in the brain. With treatment initiated 12 hr after inoculation and continued for 4 consecutive days, aciclovir administered subcutaneously in daily doses ranging from 40 to 100 mg/kg led to 21-day survival rates of from 33 to 73% and reduced virus titers by 1 to 1/2 x 4 logs on postchallenge day 8. The therapeutic accomplishments of the 100-mg/kg doses of aciclovir were comparable to those of 1,000-mg/kg doses of vidarabine (9-β-D-arabinofuranosyladenine); however, as measured by impact on body weight, aciclovir was better tolerated than vidarabine at these similarly effective doses.
Original language | English (US) |
---|---|
Pages (from-to) | 775-779 |
Number of pages | 5 |
Journal | Antimicrobial agents and chemotherapy |
Volume | 15 |
Issue number | 6 |
DOIs | |
State | Published - 1979 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases